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ABSTRACT 
IDIOPATHIC PULMONARY FIBROSIS: 
DIAGNOSIS, MANAGEMENT, AND THE SEARCH FOR A CURE 
Daniel Fioret 
August 2, 2012 
Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease with poor prognosis. 
To address this disease broadly, the candidate engaged in clinical work, literature 
analysis, database analysis, and laboratory work. The clinical work culminated in a case 
report that highlights the controversies inherent in the diagnosis and treatment of IPF. 
The literature analysis discusses ongoing clinical trials and challenges inherent in the 
management of IPF. Evaluation of a national database unveiled information about the 
burden of IPF on the healthcare system. Finally, the laboratory work examined the role 
of oxidant stress and the interaction of lung fibroblasts and lung cancer cells. Altogether, 
the document defines the clinical presentation of IPF, summarizes current treatment 
strategies and obstacles to the development of effective therapies, describes the burden of 
IPF to healthcare regarding hospitalization rates and costs, and beings to elucidate 
mechanisms by which IPF patients are more susceptible to lung cancer. 
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IDIOPATHIC PULMONARY FIBROSIS: 
DIAGNOSIS, PATHOGENESIS AND THE SEARCH FOR A CURE 
Idiopathic pulmonary fibrosis (IPF) is a disease with high mortality and of 
unknown etiology. Research efforts attempting to elucidate the mechanisms· behind the 
development of this lethal fibrotic disease have yet to determine a definitive mechanism. 
It is likely that there are multiple mechanisms by which the disease can progress, which 
may explain the fact that no single intervention has been proven effective. Therefore, 
although researchers and clinicians have been working on this disease for several decades 
and this has resulted in improved classification and identification of IPF patients, clinical 
outcomes remain unchanged. 
It is evident that a narrow approach to furthering knowledge about IPF is not 
sufficient. Furthering understanding of this disease by multiple strategies will result in 
improved outcomes for these patients faster than by one method alone. We wanted to 
learn more about the presentation and management of these patients as well as the impact 
of the disease to healthcare in the u.s. We hyPothesized that IPF hospitalization rates 
and costs were increasing and, if so, this should serve as a justification for further efforts 
to address this devastating disease. To test our hypothesis, a multi-step approach was 
used. This document analyzes the disease from the standpoint of the patient, and then 
expands into current management/treatment options, followed by an analysis of the 
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burden of the disease using a national hospital database. It concludes with an investigation of the 
cellular effects of oxidant stress, a mechanism implicated in the pathogenesis of IPF and its 
consequences. Altogether, this thesis helps to improve knowledge about identification, clinical 
management, healthcare burdenlhospitalization statistics and disease pathogenesis. 
INTRODUCTION 
IPF is a chronic and progressive pulmonary disease characterized by progressive 
deterioration of respiratory function due to lung fibrosis. More than 150,000 Americans are 
affected by IPF, which is the most common and severe form of the idiopathic interstitial 
pneumonias [1]. The progressive fibrosis typical of IPF results in dyspnea that ultimately causes 
to respiratory failure (and death) within 3 to 5 years of diagnosis in patients with advanced 
disease [2, 3]. The situation is further complicated, since there are no FDA approved drugs to 
treat IPF: Lung transplantation and oxygen supplementation are the only treatment options that 
have been shown to benefit patients with IPF. 
Because of its progressive nature and the lack of effective therapies, an early and accurate 
diagnosis of IPF is crucial. A typical patient with IPF is older than 50 years and bibasilar 
crackles can be heard during the physical examination. Imaging studies reveal bilateral 
infiltrates with peripheral and basilar predominance, traction bronchiectasis and honeycombing. 
Physiological abnormalities with a restrictive pattern are common and often associated with 
hypoxemia at rest or during exertion. Lung histology reveals heterogeneous distribution of lung 
fibrosis, honeycombing, fibroblastic foci and a paucity of inflammation; this pattern is known as 
a pattern of usual interstitial pneumonitis (VIP) [4]. 
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A diagnosis of IPF is difficult, because the clinical manifestations are similar to other 
conditions (e.g., sarcoidosis) and is in part a diagnosis of exclusion [5]. Other conditions that 
resemble IPF are interstitial lung diseases related to connective tissue disorders such as 
rheumatoid arthritis, systemic lupus erythematosus and progressive systemic sclerosis, and 
conditions triggered by environmental exposures, such as chronic hypersensitivity pneumonitis 
[6, 7]. An accurate diagnosis of IPF is important considering the differences in prognosis, IPF 
shows only a -50% 3-year survival rate. More importantly, no therapies have been proven to 
reverse, halt or delay the progression of disease in IPF in large, well-conducted, double-blinded, 
placebo-controlled, prospective clinical trials [3, 8]. 
Diagnosing IPF requires three main criteria: I? The exclusion of other known sources of 
interstitial lung diseases (including occupational, environmental, and drug toxicities obtained 
through a thorough patient history); 2, A pattern of usual interstitial pneumonia on high-
resolution computed tomography (HRCT) (if a surgical lung biopsy is not available/safe to 
obtain); 3, Specific combinations of patterns from HRCT and surgical lung biopsy when both 
tests are available. Diagnostic accuracy can be further improved with multidisciplinary talks 
. between specialists [3]. 
Herein, we describe our attempts to understand IPF through the description of a case and 
a summary of the treatment/management options currently available to these patients, the 
obstacles inherent in developing safe and effective therapies. Afterwards, we discuss the burden 
of the disease focusing on hospitalization rates and costs in the U.S. We end by an exploration 
of the role of oxidant stress in disease pathogenesis. 
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METHODS 
The data prepared for this thesis were generated through independent but 
complementary activities: 1) Review of current literature, 2) Exposure to IPF patients at the 
clinic, 3) Preparation of a manuscript that describes an IPF patient's presentation, 4) Preparation 
of a manuscript that summarizes the current understanding of IPF treatment, 5) Analysis of a 
national database to determine the impact of IPF on hospitalization costs, and 6) Investigation of 
fibrosis through laboratory work. This work was furthered through interactions with Dr. Roman 
and his colleagues at the clinic as well as in the laboratory. The experience culminated with the 
presentation of this work at several local and international venues and the publication of 
manuscripts in the area of IPF (2 published, 1 submitted, 1 in preparation). 
1. Literature Review 
My initial introduction to the fibrotic lung disease known as IPF began at the start of my 
projects with Dr. Roman. I initially devoted my efforts to researching the available literature 
related to IPF. I focused my search through PubMed and began looking at review articles and 
currently published papers related to IPF. In addition, Dr. Roman helped to focus my search 
with suggested articles to read. This led to a better understanding of the disease and also 
complimented the time I spent shadowing Dr. Roman at his pulmonary clinic. 
2. Clinical Shadowing 
The opportunity to add to my literary studies with direct patient interaction was as 
rewarding as it was informative. I joined Dr. Roman at his clinic once a week and was able to 
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watch his interaction with his patients, several of whom had IPF. Dr. Roman was an excellent 
teacher and helped me to better understand the role of a physician in the management of a 
chronic deadly disease. One of the patients that I had a chance to meet served as an example of 
an IPF patient for the clinical case report I helped write. 
3. Preparation of Clinical Manuscript [9] 
To prepare the clinical manuscript describing a patient with IPF, I utilized the physician 
notes and laboratory write-ups about the patient. I summarized the relevant information as well 
as adding relevant introductory and discussion sections to complement the clinical data. 
4. Preparation on Manuscript of IPF Management [10] 
My efforts studying the available literature also allowed me to write an article on the 
management of IPF in the clinical arena. The article summarized the current treatment options 
and strategies for IPF along with an update about the available drugs being tested for the 
treatment ofIPF. 
5. Analysis of National Database to Determine the Impact of IPF on Hospitalizations 
[11] 
To address trends related to IPF on a broad scale, I utilized a hospital database known as 
the Healthcare Cost and Utilization Project Network (HCUPnet) database. Data available 
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through the HCUPnet Database provide access to national hospitalization data in the U.S. 
between 1993 and 2008. We analyzed data related to ICD-9-CM codes for post inflammatory 
pulmonary fibrosis (PPF, ICD-9 code 515) and idiopathic fibrosing alveolitis (IFA, ICD-9 code 
516.3) and compared them to those of sarcoidosis (ICD-9 code 135). 
6. Investigation of Fibrosis through Laboratory Work 
To help address the lack of understanding of disease pathogenesis, I also devoted time to 
laboratory research. My efforts focused on working with mouse and human fibroblasts with an 
"IPF phenotype". We received several human fibroblast cell lines from patients with IPF. We 
found it difficult to work with cell lines from the human patients perhaps due to cell aging. The 
cells appeared to be stuck in a state of relative senescence and only some of the cell lines would 
grow at any noticeable rate. As a result of this, my work centered on recreating the conditions of 
an IPF phenotype in mouse fibroblasts focusing on oxidant stress. 
6.a. Specific laboratory methods 
The laboratory experiments necessary for this study involved cell culture, proliferation 
assays, Western blot, and an apoptosis assay. Detailed methods for each of these techniques are 
described in the section about laboratory work towards identifying targets for intervention later 
in this paper. 
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BODY OF THESIS 
CASE REPORT 
[9] - Fioret, D., et aI., A case of progressive lungjibrosis. Am J Med Sci, 2011. 341(6): p. 
428-30. 
A 73-year-old obese white man with a history of high blood pressure came to the 
hospital after noticing a lump on his chest. A biopsy of the lump proved it to be 
harmless, but the chest radiograph revealed lung abnormalities that prompted a chest 
tomogram and further evaluation. Ultimately, a video-assisted thoracoscopy-guided lung 
biopsy was performed that revealed alternating areas of relatively normal lung mixed 
with a patchwork of parenchymal tissue involvement by end-stage honeycombing. Areas 
of active fibrosis with fibroblastic foci and collagen deposition were also seen in addition 
to mild inflammation consistent with a pattern of usual interstitial pneumonia. The 
patient was given a diagnosis of IPF and sent to the University of Louisville Interstitial 
Lung Disease Center for further management. 
On evaluation, the patient complained of dyspnea on exertion that had been 
worsening over the past 2 years. Mild cough was present, but no other symptoms 
suggestive of infection or heart disease were elicited. He had a history of tobacco use 
that involved smoking 6 to 8 cigarettes a day for more than 30 years; he quit smoking 22 
years ago and was not drinking alcohol or taking alternative medicine therapies. During 
questioning about occupational and environmental exposures, the patient acknowledged 
working on a farm and being exposed to hay, cattle and other animals on a regular basis 
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throughout his life. Prescribed medications included fluticasone and salmeterol inhalation 
once daily, a tablet combining valsartan and hydrochlorothiazide for hypertension, 
diltiazem, Turns, and omeprazole for acid indigestion and gastro-esophageal reflux 
disease, pentosan polysulfate sodium, acetylsalicylic acid, fish oil and a multivitamin. 
The initial physical examination showed normal vital signs with a hemoglobin 
oxygen saturation at room air and at rest value of 94% and a respiratory rate of 14 
breaths/min. His head examination revealed no lesions, but he had a slightly narrowed 
oropharynx. Examination of the neck revealed no jugular venous distention, 
lymphadenopathy or thyromegaly. His heart rate was regular, but showed a systolic 2/6 
murmur that was most noticeable in the left sternal border. The lung examination 
revealed bibasilar inspiratory crackles but no ronchi or wheezes. The abdominal 
examination was benign. Extremities showed no edema, and his fingers showed 
borderline clubbing. His electrocardiogram revealed a heart rate of 61 beats/min but was 
otherwise normal. A right and left heart catheterization performed by his cardiologist for 
atypical chest pain revealed mild disease in the right coronary artery and the circumflex 
artery, as well as moderate disease in the mid left anterior descending coronary artery. 
The study also revealed evidence of very mild pulmonary hypertension. 
During his initial visit, pulmonary function tests revealed no obstruction, but the 
total lung capacity was decreased (4.19 L), and the ditIusion lung capacity was severely 
reduced (l0.04 40% predicted). These results were interpreted as consistent with a 
severe restrictive ventilator pattern and severe reduction in diffusing capacity. More 
importantly, the results were dramatically decreased from those obtained 4 years earlier 
which showed a total lung capacity of 5.2 L (78% predicted) and a normal diffusion lung 
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capacity (24.7, 119% predicted). The patient's blood gas showed a pH of 7.429, PC02 of 
37.4 and a P02 of 65. A 6-minute walk test revealed mild hemoglobin oxygen 
desaturation to 90%. A chest tomogram revealed fibrotic lung changes with peripheral 
distribution and basilar predominance, honeycombing and traction bronchiectasis. 
After evaluation of his overall clinical picture, imaging studies and histology, a 
diagnosis of IPF was confirmed. Treatment options were discussed, and the patient opted 
for participating in a placebo-controlled randomized clinical trial. A few weeks after 
inclusion in the trial, the patient developed swelling and a white exudate over his tongue, 
considered to be candidiasis, for which he was treated with fluconazole. The exudates 
cleared, but the patient had 2 episodes of worsening shortness of breath for which his 
primary physician gave him intramuscular steroid injections. 
Approximately 2 months after inclusion m the trial, the patient developed 
significant shortness of breath on exertion that was persistent and associated with 
increased nonproductive cough and significant fatigue. Pulmonary function tests 
revealed further deterioration. During a 6-minute walk test, his hemoglobin oxygen 
saturation (initially at 93 %) dropped to 71 % within 2 minutes. Because of the possibility 
of an "exacerbation of IPF," the patient was admitted to the hospital where he underwent 
an extensive evaluation. A chest tomogram using a protocol to detect pUlmonary 
embolism revealed the earlier reported changes of fibrosis but no new infiltrates, ground 
glass opacification, pleural effusion or other abnormalities, including pulmonary 
embolism (Figure 1). An echocardiogram failed to reveal a cardiac etiology for his 
deterioration and sputum, and blood cultures showed no organisms. A bronchoscopy 
revealed significant airway erythema and some yellowish secretions. The patient was 
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Figure 1 





In idiopathic pulmonary fibrosis HRCT typically shows bilateral infiltrates 
predominating in the periphery (image A), limited disease in the upper lobes (image B) 
and worsening infiltrates toward the lung bases (C). Fibrosis is noted mainly at the bases 
where honeycombing is observed (C). 
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gIven a diagnosis of severe acute bronchitis and was started on antibiotics and 
intravenous steroids. After 3 days hospitalization, the patient was discharged home on 
supplemental oxygen and oral antibiotics to be followed in clinic. After initial 
improvement, the patient has continued to deteriorate with worsening dyspnea on 
exertion and has increased requirements for oxygen supplementation. 
DISCUSSION 
IPF has received a great deal of attention lately due to the recognition that this 
deadly illness affects more than 150,000 Americans, that its incidence is increasing, [1] 
and by the increased number of clinical trials available to patients. Despite the above, 
this case highlights many of the difficulties inherent in the diagnosis and management of 
patients with IPF. Often, and despite increased awareness about the disease, patients with 
IPF have symptoms for more than 2 years before a diagnosis is made. Diagnosis is 
delayed because of the slow insidious course of the disease in an aging population (IPF 
occurs mainly in subjects older than 50 years) that often has an increased frequency of 
exercise-limiting conditions, such as heart disease [12]. 
An early diagnosis of IPF is important, given differences in prognosis and in 
management with earlier detection. The 3-year survival rate for IPF is ~50%, and it has 
no cure, whereas survival is better in other idiopathic interstitial pneumonias and related 
interstitial disorders [2]-[3]. Also, there is no effective therapy for IPF, whereas 
immunosuppression may be effective in other conditions associated with lung 
inflammation and fibrosis [12]-[13]. 
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An accurate diagnosis of IPF requires a thorough patient history and physical 
examination, and a careful analysis of diagnostic examinations and imaging studies. The 
patient history should include job history, smoking and drinking habits, associated 
diseases, family medical history and any exposure to environmental or occupational 
irritants such as metal dusts, paints and animals/pets. The latter is especially important as 
these exposures may cause conditions that could be confused with IPF such as chronic 
hypersensitivity pneumonitis, a disorder included in the differential diagnosis of our case 
[3]. 
A thorough evaluation for autoimmune causes of pulmonary fibrosis that includes 
scleroderma, rheumatoid arthritis and systemic lupus erythematosus should be 
undertaken. The clinical history is most critical here, and a screening antinuclear 
antibody and rheumatoid factor serology, among other serologies, should be obtained [3]. 
The physical examination is not particularly revealing, except for the presence of 
bibasilar crackles, which sometimes leads to the erroneous diagnosis of congestive heart 
failure [14]. Digital clubbing is relatively frequent (25-50% of patients) but is not 
specific to, or necessary for, the diagnosis of IPF [12]. Pulmonary function tests usually 
reveal a restrictive pattern and marked decrease in gas transfer as measured by the 
diffusing capacity for carbon monoxide. Hemoglobin oxygen saturation should be 
evaluated both at rest and exertion as abnormalities may only be detected during exertion 
during the early stages of the disease. 
Chest radiography is useful, but it may overlook significant changes. It typically 
shows bilateral reticular infiltrates (typically peripheral and basilar) and small lung 
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volumes. Upper lobe predominance or the presence of other findings such as significant 
lymphadenopathy, pleural effusions and/or calcifications and cardiomegaly should point 
to alternative diagnoses. A high-resolution chest tomogram (HRCT) is crucial for the 
evaluation of subjects with interstitial lung disease [3]. In IPF, typical chest tomography 
findings include bilateral peripheral infiltrates with basilar predominance associated with 
traction bronchiectasis and, often, honeycombing. In the right clinical setting, and if the 
fibrosis is considered idiopathic, a chest tomogram with the above findings is sufficient to 
confirm the diagnosis of IPF [15]. In the absence of the typical findings on HRCT, and 
especially if ground glass opacification is present, a surgical biopsy might be necessary 
for establishing the diagnosis. However, the benefits of a surgical biopsy must be 
weighed against the risk of the procedure, and the age of this population and 
accompanying medical conditions such as heart disease, hypertension and diabetes must 
be taken into consideration. 
Bronchoscopy, bronchoalveolar lavage and transbronchiallung biopsy are helpful 
to rule out infection and granulomatous disorders (e.g., sarcoidosis) but rarely provide 
sufficient material to evaluate histological patterns that is crucial for an accurate 
diagnosis of the idiopathic interstitial pneumonias. It is for this reason that a surgical 
biopsy is often considered for a definitive diagnosis [16-18]. As in our patient, histology 
shows a pattern of usual interstitial pneumonitis, which is characterized by heterogeneous 
distribution of fibrosis, paucity of inflammation, the presence of fibroblastic foci and 
honeycombing. However, this histological pattern is not entirely specific and may be 
elusive even in the hands of the most experienced pathologists [19]. Figure 2 
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Figure 2 
Evaluation schematic for patients suspected of interstitial lung disease (lLD) 
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The pulmonary history is paramount in the evaluation oflLD. Initial laboratory work 
should include a complete metabolic profile (Comp panel) and antinuclear antibody 
(ANA) and rheumatoid factor (RF) screen. A postero-anterior (P A) and lateral chest film 
will define the diffuse bilateral abnormalities typical of the ILD, and the high-resolution 
computerized tomogram (HRCT) adds specificity and can resolve abnormalities not seen 
on plain film. When tissue is needed for diagnosis and management decisions, the patient 
is referred for biopsy. Transbronchiallung biopsy (TBLB) is the procedure of choice 
when there is suspicion of granulomatous disorder such as sarcoidosis. Surgical lung 
biopsy (SLB) is preferred for diffuse nongranulomatous ILD such as idiopathic 
pulmonary fibrosis (IPF) or the other idiopathic interstitial pneumonias (lIPs). 
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demonstrates a relatively straightforward evaluation for interstitial lung diseases such as 
IPF. 
In general, IPF is a slowly progressive disorder that manifests as progressive 
dyspnea on exertion and exercise intolerance culminating after a few years in respiratory 
failure. However, in a minority of patients (perhaps 15%), the natural history of the 
disease differs. In such cases, IPF may progress through unexpected episodes of 
deterioration characterized by acute worsening of exercise intolerance (usually within 30 
days before medical evaluation), decreased oxygen hemoglobin saturation and HRCT 
with new infiltrates and/or ground glass opacification [3]. After exclusion of other causes 
(e.g., infection, pulmonary emboli and congestive heart failure), this rapid deterioration is 
likely related to what has been termed as "exacerbation of IPF ," an entity that carries a 
worse prognosis, due to faster progression of disease [20, 21]. As was the case in our 
patient, and because of its importance, patients showing deterioration should be evaluated 
for exacerbation of IPF. Because IPF is considered a diagnosis of exclusion, tests should 
be ordered to rule out other conditions such as infection (often by bronchoscopy), 
thromboembolic disease or congestive heart failure. 
Despite the lack of proven effective therapies, there is still much that can be done 
for patients with IPF. Initially, effort should be given to confirming the diagnosis by 
reviewing all data available, and by evaluating imaging studies and histology, if 
available. The need for oxygen supplementation, evaluation for pulmonary rehabilitation 
and candidacy for lung transplantation (an effective but limited surgical option) should be 
considered early. Importantly, education about the disease and its prognosis should be 
provided, and avoidance of toxic agents (e.g., tobacco) should be encouraged. An early 
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evaluation for related conditions is also important including pulmonary hypertension 
[22]. As there are no proven effective medical therapies for IPF, patients should be 
considered for inclusion in clinical trials. 
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MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS [10] 
CHALLENGES IN TRANSLATING PRECLINICAL TRIALS 
TO EFFECTIVE DRUG THERAPIES 
Before the 1990s, many patients with pulmonary fibrosis of unknown etiology 
were diagnosed with IPF and were often treated with high doses of steroids. However, 
although some patients showed improvement, others showed continuing deterioration 
despite similar clinical presentation and treatment. This led many to conclude that 
patients initially diagnosed with IPF actually suffered from a variety of conditions; some 
steroid responsive, others less responsive [23]. This new understanding prompted the 
careful analysis of the histology of subjects diagnosed with IPF, which ultimately led to 
the classification of the idiopathic interstitial pneumonias, of which IPF is a member [12]. 
In contrast to other idiopathic interstitial pneumonias, IPF shows a characteristic 
histological pattern termed usual interstitial pneumonia (VIP). Later clinical studies that 
considered histological diagnosis showed that patients diagnosed with IPF in association 
with histology of VIP represented the most common subgroup of patients with idiopathic 
interstitial pneumonias and, importantly, the one with the worse prognosis. Specifically, 
although no well-controlled prospective studies were conducted, a general consensus 
grew about the lack of responsiveness of IPF to steroids. Despite the above, and 
considering the lack of effective therapies, many patients with IPF are currently treated 
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with steroids and/or other immunosuppressants pending the identification of new 
therapies. It is for this reason that a stronger emphasis is being placed on the conduct of 
clinical trials designed to evaluate prospectively the safety and effectiveness of new 
therapies [8]. To date, these efforts have failed to unveil a "magic bullet" but much has 
been learned through these trials, which have helped shape the standard of care for this 
condition. 
THE SEARCH FOR EFFECTIVE THERAPIES IN IPF 
There are a variety of new studies testing treatment options for IPF. 
Clinicaltrials.gov, a registry of federally and privately supported clinical trials, lists 90 
currently recruiting (active) or recently completed studies of IPF 
(http://clinicaltrials.gov). The trials listed show how changing ideas about the 
pathogenesis of this condition have shaped our approach to therapy. For example, it was 
originally thought that IPF was caused by relentless inflammation, and this explains why 
early clinical trials often involved anti-inflammatory agents such as corticosteroids. 
These early studies were often flawed by misclassification of patients with or without 
IPF, as well as the lack of placebo control groups, but recent publications suggest that 
there is no apparent benefit of corticosteroid use for treatment of IPF [23]. Subsequent 
studies testing other anti-inflammatory agents (e.g., etanercept, interferon-y and 




Drugs found to be ineffective in the treatment of IPF 
Medications Results 
IFN-y* vs. placebo [25] No increase in survival 
Study Comments 
New study testing IFN-y by 
an inhaled route is planned 
Bosentan vs. placebo [26] No change in 6MWT* seen New study is testing to see 
whether Bosentan delays 
time until death/decreases 
lung deterioration 
Imatinib vs. placebo [27] Negative study 
Prednisolone + IFN-y Inconclusive results 
vs. Prednisolone + Colchicine [28] 
NAC*, azathioprine, Increased mortality vs. 
+ prednisone vs. placebo [29] placebo group 
Warfarin vs. placebo [30] Negative study 
Trial testing NAC alone vs. 
placebo undergoing 
Warfarin appeared to 
increase mortality due to 
respiratory worsening. 
Didn't include patients 
requiring warfarin for non-
IPF related treatments. 





Drugs requiring further investigation in the treatment of IPF 
Medications 
Etanercept vs. placebo [24] 
Prednisone + azathioprine vs. 
prednisone + placebo [31] 
Prednisolone + anticoagulant vs. 
prednisolone [32] 
Pirfenidone vs. placebo [33] 
Results Study Comments 
Improved FVC* and DLco* Original study did not reach primary end point 
Trend to improved resting arterial Small test group, only a trend toward 
02, small increase in survival improvement, changes not significant 
Significant increase in survival Not a double-blinded study. Diagnostic criteria 
used were not standard 
Improved lung function variables Primary end points for study were atypical and 
were not met. 22% of the patients stopped 
participating in the study 
N-acetylcysteine vs. Bromhexine [34] No improvement in pulmonary 
function tests or quality of life 
May delay disease progression in N-acetylcysteine 
group 
*DLco, diffusing capacity for carbon monoxide; FVC, forced vital capacity 
N ..... 
Table 3 
Drugs considered to have some efficacy but require further testing 
Medications 
Pirfenidone vs. placebo [35] 
Results 
Less of a decrease in %FVC*, 
Fewer deaths in high dose group 
Prednisolone +IFN-y* vs. prednisolone [36] Significant improvement in lung 
function for combination drug 
patients 
Study Comments 
Approved treatment in Japan, more side effects in 
high dose group. No FDA * approval 
N= 18, significant improvement atypical. 
Retesting with a larger patient group advisable 
and include a double-blinded, placebo control 
Azathioprine, prednisone, + NAC* vs. Decreased decline in FVC and Lack of a placebo-only control group 
Azathioprine, prednisolone, + placebo [37] gas transfer for CO* deterioration 
in the non-placebo group 
*IFN, interferon; NAC, N-acetylcysteine; FVC, forced vital capacity; CO, carbon monoxide; FDA, food and drug administration 
Knowledge has accumulated suggesting that tissue fibrosis can occur without 
inflammation or dissociated from it. In fact, in cases where IPF is suspected, significant 
tissue inflammation should lead clinicians to search for an alternative diagnosis. Despite 
the above, a statement published by the American Thoracic Society/European 
Respiratory Society in 2000 suggested the use of low-dose prednisone (a corticosteroid) 
with azathioprine (an immunosuppressant) for treatment. This combination became a 
standard therapy largely due to the lack of available treatment options. However, in 
2008, the Idiopathic Pulmonary Fibrosis International Group Exploring N-acetylcysteine 
I Annual Study tested the addition of an antioxidant, N-acety1cysteine, to the standard 
regimen [37]. Although this study showed delays in the progression of IPF, it was 
heavily criticized for its small size and for the lack of a control group. Nevertheless, 
despite the lack of proven effectiveness, this new, largely untested, treatment regimen 
including N-acety1cysteine (NAC) evolved as the standard of care. Unfortunately, a 
recent randomized, double-blinded, placebo-controlled trial testing the effect of this 
combination therapy (prednisone, azathioprine, and NAC) was stopped prematurely due 
to an increased rate of death in the combination group versus placebo (8 vs. 1 patients). 
In addition there was no physiological or clinical benefit seen in the combination group 
and combination therapy patients had increased adverse events [29]. However, a separate 
study comparing the use of only NAC versus placebo is still ongoing [29]. A similar 
situation has recently evolved regarding the use of warfarin (an anticoagulant) in the 
treatment of IPF [38]. Previous findings had suggested a potential benefit of warfarin in 
a subset of patients (receiving a weak negative recommendation [3]), however, recent 
evidence has shown that warfarin therapy shows no clinical efficacy and is associated 
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with an increased risk of mortality (excluding IPF patients that required anticoagulation 
for non-IPF related reasons) [30]. 
As other concepts about IPF pathogenesis emerged, phase I, phase II and phase III 
clinical trials have been conducted to test their accuracy. In general, the agents tested 
show benefits when examined in animal models of lung fibrosis. These include inhibitors 
of fibrotic growth factors (e.g., connective tissue growth factor, transforming growth 
factor ~ and platelet-derived growth factor), endothelin receptor antagonists (e.g., 
bosentan), inhibitors of kinases (e.g., imatinib), anticoagulants (warfarin) and 
antifibrotics (e.g., pirfenidone) [8, 26, 27, 32, 39]. Unfortunately, benefits have not 
always been observed in these studies, improved survival has not been demonstrated and 
much controversy still remains. However, the data generated suggest that some of these 
approaches should be considered further. More importantly, these studies have prompted 
the generation of new and testable hypotheses about IPF pathogenesis. 
There are several important factors to consider when designing a new study. Of 
particular importance is the use of a placebo-only control group. Also, a standard or at 
least a minimum criterion for primary endpoints should be established. Although 
enhanced survival is the most robust endpoint for a trial, other factors such as a change in 
forced vital capacity or performance on 6-minute walk test and possibly the use of 
biomarkers (once suitable markers are identified) should be considered for use as primary 
and secondary endpoints. 
Clinical studies are often limited by a small sample size, especially in the case of 
a disease such as IPF. In part, the limited number of patients available for participation in 
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trials is addressed by involving multicenter clinical trials. Collaboration between 
different centers can and should be encouraged. Recruitment criteria are established and 
include confirmation of a diagnosis of IPF in all the participating patients. Until effective 
treatments are found, attention should be given to the treatment of comorbid conditions. 
A recent clinical trial tested the ability of Sildenafil, a phosphodiesterase-5 inhibitor, to 
improve patients with advanced IPF. The primary outcome was not achieved; however, 
small but significant differences in arterial oxygenation, carbon monoxide diffusion 
capacity, degree of dyspnea and measures of quality of life were seen [13]. 
IPF, as the name suggests, has no known cause. Nevertheless there are several 
factors that are associated with a greater risk for disease development and progression 
including male gender, genetic mutations, smoking, and gastrointestinal reflux disease [3, 
40-42]. In certain subjects, pulmonary fibrosis develops from known pro-fibrotic stimuli 
such as allergens, asbestos, and drugs, or is associated with chronic inflammatory 
conditions such as connective tissue disorders [43,44]. 
THE IMPACT OF GENETICS 
A genetic association of IPF is seen in less than 5% of all patients with the disease 
although higher numbers (~20%) have been reported in some smaller cases. The familial 
form, as defined by affecting two or more members of the same biological family, is 
histologically and clinically identical to the sporadic form of IPF [45]. Evidence now 
suggests that mutations in two separate gene pathways both lead to the common 
phenotype of IPF. These mutations occur in the genes encoding lung surfactant proteins 
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C and A2 which lead to increased endoplasmic reticulum stress in type 2 alveolar 
epithelial cells (these mutations are found almost exclusively in familial cases of IPF). 
The other mutations occur in genes that encode telomerase (TER T and TERC) which are 
believed to cause IPF by the shortening of telomere lengths in lung stem cells (the 
majority of these cases are found in familial IPF). Interestingly, short telomere lengths 
are found in both familial and sporadic IPF even in the absence of the telomerase 
mutation. This suggests a connection with the age-related prevalence of IPF [46]. It is 
important to note that the surfactant and telomerase mutations account only for ~ 15-20% 
of all familial IPF cases. Thus, there are likely several other genes responsible for the 
development ofIPF. In addition, although these mutations are significantly less prevalent 
in sporadic IPF, the pathways that are involved with these genes are often dysfunctional 
[47]. 
Race appears to playa role in patient survival and outcome. The three-year 
survival rate was found to be ~45% for Non-Hispanic whites versus ~35% for Non-
Hispanic Blacks and Hispanics [48]. In addition, race has an effect on survival following 
lung transplantation. Black and Hispanic patients with advanced IPF have shorter 
survival times following lung transplantation. The 2-year survival estimate for Blacks 
and Hispanics was 30% versus 82% in Whites and Asians [49]. 
OTHER IMPORTANT CONSIDERATIONS REGARDING IPF MANAGEMENT 
The lack of Federal Drug Administration-approved medications for the treatment 
of IPF does not mean that physicians have nothing to offer in this setting. This is far 
25 
from the case considering that lung transplantation and oxygen supplementation have 
been shown to extend survival in these patients [50]. In addition, these and other 
interventions can improve quality of life. Thus, it is important that patients suspected 
and/or diagnosed with IPF be referred to centers with expertise in this field, so that 
patients are evaluated thoroughly and appropriate treatment strategies are considered. 
The general management of IPF is summarized in Figure 3 and specific interventions are 
described later. 
OXYGEN THERAPY 
As the disease progresses, IPF causes dyspnea on exertion mainly due to increases 
in the work of breathing and alterations in gas exchange capacity and hypoxemia. In this 
setting, supplemental oxygen therapy is useful as it may diminish dyspnea and improve 
exercise tolerance. However, the need for supplemental oxygen may be missed if 
patients have only resting arterial blood gas or oxygen saturation measurements. Patients 
should be tested for supplemental oxygen using a 6-minute walk test, a test that evaluates 
distance walked and hemoglobin oxygen saturation during exertion. Oxygen 
supplementation should be considered in patients who show hemoglobin oxygen 
de saturation below 88% (or P02 <55 mm Hg) [3]. Oxygen can be given nasally, through 
a mask or in some cases by transtracheal delivery. The amount of time required to use 
the oxygen delivery system depends on the condition of the patient's disease. Initially, it 
may only be required during strenuous activities, but as the disease progresses, it may be 
required more often or continuously. Oxygen may be supplied by a stationary 
concentrator for home use and portable tanks of compressed gas. When higher flow rates 
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Figure 3 
General management of patients with IPF 








Consider if candidate 
for pulmonary rehabilitation 
Determine candidacy 
for lung transplantation 
Evaluate other problems 
(e.g., cough, pulmonary 
hypertensio n) 
Consider clinical trial 
Once identified, patients suspected of IPF should be evaluated to confirm the diagnosis. 
If confirmed, attention should be given to education and evaluation for the need for 
oxygen supplementation and candidacy for pulmonary rehabilitation and lung 
transplantation. Control of cough and early detection of associated conditions (eg, 
pulmonary hypertension) should be considered. Finally, until an effective drug becomes 
available, patients should consider participating in clinical trials. 
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(4-5 Llmin) are needed at rest or long portable times are required, a liquid oxygen setup 
is appropriate. 
PULMONARY REHABILITATION 
The benefits of physical rehabilitation have not been widely studied; however, 
pulmonary rehabilitation is considered important in building and maintaining aerobic and 
physical fitness and treatment of dyspnea in select patients [51]. Training usually 
involves breathing exercises, physical conditioning and anxiety and depression 
management. Similar to the necessity of talking to patients who convey an understanding 
of their treatment options, pulmonary rehabilitation is essential in helping patients 
manage their condition and maintain the highest quality of life possible. 
COUGH SUPPRESSION 
One of the most distressing and difficult-to-treat consequences of IPF is cough. 
Cough has a measureable impact on the quality of life and correlates with cough 
frequency as determined by cough counts or perception of cough frequency by patients 
[52]. The mechanisms of cough in IPF are not well understood, but the triggers for this 
symptom reside in the airways as demonstrated by cough challenge tests using capsaicin. 
Patients with IPF show a 30-fold increased sensitivity (i.e., 30 times lower dose versus 
healthy subjects) to cough inducing levels of capsaicin [53]. Even though chronic cough 
is a major symptom of IPF, approximately one half of the cases of chronic cough in IPF 
can be attributed to more common causes such as hyperresponsive airways, 
gastroesophageal reflux and rhinosinusitis [54]. The management of cough in IPF 
should, therefore, include a careful evaluation for the other causes of chronic cough. 
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Treatment of chronic cough due to IPF is difficult, and common treatments often fail. 
Ironically, systemic steroids that have no impact on the course of IPF may be effective in 
mitigating cough in this disease [55]. 
LUNG TRANSPLANTATION 
Lung transplantation is the closest option to a cure for IPF; however, there are 
several limitations to this treatment option. IPF is a disease that is predominantly 
associated with older age with the median age being 66 years at diagnosis [56]. 
Advanced age, along with the frequency of comorbid conditions (i.e., pulmonary arterial 
hypertension, cardiac disease) increase the complications and risks associated with 
surgery [57]. This also results in worse outcomes for IPF patients following 
transplantation compared with other respiratory conditions [58]. 
SUMMARY 
IPF is a chronic disease characterized by progressive lung fibrosis. Studies in 
animals have unveiled drugs that might be helpful in preventing lung fibrosis. 
Unfortunately, these studies have not been duplicated in humans, and, to date, clinical 
trials have failed to unveil a drug capable of improving survival. Consequently, lung 
transplantation and oxygen supplementation remain the only therapeutic options capable 
of improving survival in patients with IPF. Despite this, there is still much that can be 
done to improve the quality of life in these patients including physical rehabilitation and 
control of cough (Figure 3). Also, patients may benefit from the early detection and 
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treatment of secondary problems (e.g., pulmonary hypertension). Until a therapy is 
found, patients with IPF are encouraged to engage in well-conducted clinical trials that 
may someday unveil a safe and effective treatment for this devastating disease. 
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IMPACT TO HEALTHCARE 
National Database (Health care Cost and Utilization Project) 
The burden placed on the healthcare system by patients with IPF is extensive. 
IPF patients are some of the most costly patients to treat during advanced stages of the 
disease. Limited treatment options and the lack of FDA approved drugs make 
understanding the impact of IPF patients to the healthcare system essential. In order to 
bridge the knowledge gap between the clinical arena and the costs associated with 
treating patients at the national level an epidemiological study using a national healthcare 
database was undertaken focusing on hospitalization rates and costs. 
HOSPITALIZATION RATES, LENGTH OF STAY, MORTALITY AND COSTS 
OF IPF IN THE UNITED STATES 
The incidence of IPF appears to be increasing although questions remain as to 
whether this is related to increased awareness or a true change in incidence ofthe disease. 
This has been influenced by the increased use of high-resolution computed tomography 
scans, which became more commonplace since the 1990s and provided an easier, more 
economical, and more accurate means of diagnosing IPF and related pulmonary disorders 
[59]. Additionally, the publication by the American Thoracic Society and European 
Respiratory Society (ATS/ERS) of an international consensus statement of the diagnosis 
and treatment guidelines for IPF in 2000 [60] and of idiopathic interstitial pneumonias in 
2002 [12] likely increased physician awareness and accurate diagnosis of the disease. 
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Current information about the morbidity and mortality of pulmonary fibrosis is needed. 
Others have reported a seasonal variation in mortality due to IPF (mortality is the highest 
during the winter) [61] and have reported the rate of mortality increasing 
between 1992 and 2000; the average age- and sex-adjusted mortality rate was 50.8 per 
1,000,000 people [62]. Furthermore, among those with IPF, Blacks are less likely to die 
from IPF than Whites, whereas Hispanics are more likely to die than Whites [63]. 
Our analysis focuses on hospital admissions, in-hospital mortality, length of stay, 
and charges associated with pulmonary fibrosis. For this, we utilized a public database 
containing hospitalization information known as the Healthcare Cost and Utilization 
Project (HCUP) Public Database. 
METHODS 
THE HCUP DATABASE 
Data available through HCUP provide access to a family of healthcare databases. 
These include the Nationwide Inpatient Sample (NIS), which contains inpatient data from 
a national sample of over 1,000 hospitals in the United States as well as the State 
Inpatient Database (SID) that contains inpatient discharge abstracts from participating 
states. Data from the databases are provided from 1988 to the present date [11]. The NIS 
is the largest all-payer inpatient care database in the United States and contains data from 
~8 million hospital stays yearly. The NIS contains data from 1,050 hospitals located in 
44 states and approximates a 20% stratified sample of U.S. community hospitals. The 
SID contains the inpatient discharge abstracts from participating states. The SID 
encompasses ~90% of all U.S. community hospital discharges. 
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PATIENT COHORT AND DATA ANALYSIS 
Using the HCUPnet Database, we analyzed data related to ICD-9-CM codes for 
post inflammatory pulmonary fibrosis (PPF, ICD-9 code 515), idiopathic fibrosing 
alveolitis (IFA, ICD-9 code 516.3), and sarcoidosis (ICD-9 code 135). We compared 
different parameters available for each disease (e.g., charges, length of stay, mortality, 
procedures, and diagnoses). We investigated changes over time for the United States (for 
those states participating in the database) between 1993 and 2008. Geographic location 
was defined as Northeast, South, Midwest, and West based on U.S. census regions. 
Classification of co-morbidities was based on the patient's secondary diagnoses. 
RESULTS 
HOSPITAL ADMISSIONS 
Analysis of the HCUPnet Database revealed an increase in the number of hospital 
discharges nationwide between 1993 and 2008 with an upsurge by the tum of the century 
(Figure 4A). During the same time period, a steady increase in hospital admissions was 
noted for patients with a principal diagnosis of PPF, doubling in the same time period and 
reached close to 30,000 admissions per year in 2008; these changes averaged to a 4.9% 
increase per year (Figure 4B). In contrast, admissions related to IF A were relatively 
stable, declined early in the past decade to 3,513 admissions per year in 2008. For 
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Figure 4 I A. Increase in the number of hospital discharges nationwide. B. Hospital 
discharges have doubled for PPF. Discharges for IF A have decreased, while sarcoidosis 
discharges have increased 1.9%/year on average. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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1.9%/year, reaching 7,588 admissions In 2008. Table 5 lists the top procedures 
performed in these patients with lobectomy or pneumonectomy, diagnostic 
bronchoscopy/biopsy of bronchus and related procedures, and intubation/mechanical 
ventilation at the top of the list. Importantly, a significant percentage of patients admitted 
with a primary diagnosis of PPF, IF A or sarcoidosis also suffered from other important 
medical conditions, such as essential hypertension, hyperlipidemia, diabetes, and 
coronary atherosclerosis (Table 6). The database also included information related to 
adverse effects of medical drugs (E code), showed that up to 16% of patients hospitalized 
for IFA suffered from this problem, which was associated with 18.63% mortality; no 
information about adverse effects of medical drugs was provided for PPF or sarcoidosis. 
When the HCUPnet Database was analyzed to evaluate the reasons for 
hospitalization, we noted that, in general, patients were hospitalized with primary 
diagnoses other than PPF, IF A or sarcoidosis. For example, there were many more 
patients hospitalized with a secondary diagnosis of IF A than those hospitalized with IF A 
as a primary diagnosis (Figure 5A). Discharges of IF A patients where IFA was not the 
principal diagnosis decreased significantly between 2003 and 2004 and reached 15,105 
by 2008. Overall, during the 15 year period examined, there was an increase in 
hospitalizations for patients with PPF, where PPF was not the principal diagnosis; from 
150,000 in 1993 to 250,000 in 2008. As observed for PPF, hospitalizations of patients 
with secondary diagnosis of sarcoidosis increased steadily in the same time period 
tripling since 1993 (28,638 hospitalizations) to 74,630 admissions by 2008 (Figure 5C). 
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Table 5 
Primary procedures for patients hospitalized with IF A *, PPF*, and sarcoidosis (2009)** 
CCS Primary Procedure Principal Diagnosis: % Total Discharges (% Mortality) 
Code IFA PPF Sarcoidosis 
36 Lobectomy or 9.0 20.7 (1.9) 5.1 
Pneumonectomy 
37 Diagnostic Bronchoscopy 5.4 6.8 11.5 
and Biopsy of Bronchus 
38 Other Diagnostic Procedures 5.6 8.8(3.1) 2.0 
on Lung and Bronchus 
216 Respiratory Intubation and 5.8 (67.1) 4.1 (49.2) 3.1 
Mechanical Ventilation 
40 Other Diag. Procedures of 0.5 8.8 
Respiratory Tract + Mediastinum 
Note: A 2::5% discharges was used as the threshold for inclusion. 




Secondary diagnoses for Qatients hosQitalized with idioQathic fibrosing alveolitis (IF A)*, 
Qostinflammatory Qulmonary fibrosis(PPF}* or sarcoidosis (2009) [11] 
CCS Secondary Diagnosis Principal Diagnosis: % of Total Discharges (% Mortality) 
Code IFA* PPF* Sarcoidosis 
131 Respiratory Failure, 47.8 (25.2) 30.1 (18.2) 14.5 (6.3) 
Insufficiency, Arrest (adult) 
98 Essential Hypertension 44.0 (14.1) 42.6 (5.8) 39.7 
53 Hyperlipidemia 36.3 (15.6) 28.2(5.1) 18.3 
127 Chronic Obstructive 35.3 (9.7) 34.4 (6.2) 18.4 
Pulmonary Disease + Bronchiectasis 
49 Diabetes Mellitus 31.5 (12.1) 24.1 (7.6) 23.2 
Without Complication 
101 Coronary Atherosclerosis 31 (16.1) 24.5 (7.6) 
257 Other Aftercare 29.5 (17.5) 20.3 (13.7) 
106 Cardiac Dysrhythmias 28.8 (23.2) 21.5 (11.2) 13.3 
663 Screening/History of Mental 28.5 (14.7) 29.9 (4.9) 
Health and Substance Abuse 
259 Residual Codes, Unclassified 27.8 (15.1) 25.5 (6.4) 27.2 
103 Pulmonary Heart Disease 27.7 (15.8) 17.4 (12.8) 13.4 
138 Esophageal Disorders 26.7 (12.7) 23 (5.3) 
108 Congestive Heart Failure, 26.4 (12.7) 23.1 (11.4) 13.1 
Non-hypertensive 
55 Fluid and electrolyte disorders 26 (25) 20.0 (13.5) 17.7 
122 Pneumonia (not TB/STDs) 25.2 (22.6) 18.7 (16.4) 14.6 
244 Other Injuries/Conditions 24.9 (17.5) 18.3 (11.5) 
Due to External Causes 
133 Other Lower Respiratory 23.1 (13.6) 16.5 (7.5) 65 
Disease 
59 Anemia 21.7 (21.2) 18.2 (9.4) 17.6 
2617 E Codes: Adverse Effects 16.1 (18.6) 
of Medical Drugs 
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Figure 5 
Hospital Discharges by Disease Condition 
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Figure 5 I A. Discharges of IF A patients where IF A was not the principal diagnosis 
decreased significantly between 2003 and 2004. B. Discharges where PPF was not the 
principal diagnosis increased overall from 150,000 to 250,000. C. Discharges for 
sarcoidosis have increased from 3,513 to 7,588. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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The above data suggested that patients with diagnosis of PPF, IF A or sarcoidosis 
are often admitted due to other conditions. Table 7 lists the top primary diagnoses for 
which patients were admitted, pneumonia, respiratory failure, chronic obstructive 
pulmonary disease, congestive heart failure and septicemia led the list. When data were 
available for an individual diagnosis (i.e., pneumonia), it was evident that subjects with 
IF A experienced the highest mortality from these conditions followed by PPF. Also, 
subjects with IF A and PPF showed the highest incidence for critical secondary diagnoses, 
such as respiratory failure. 
LENGTH OF STAY 
Length of stay during hospitalization for all conditions decreased steadily in the mid-
1990s and stabilized at 4.6 days by 2009 (Figure 6A). Length of stay for PPF, IFA and 
sarcoidosis were higher (1-3 days) than the average for all conditions during all years of 
this analysis. For PPF, length of stay decreased during the mid-1990s and remained 
relatively stable at 6 days. On the other hand, length of stay for IF A was the highest of 
this group starting at 9.7 in 1993, decreasing thereafter, only to increase again in 2007 
with an average length of stay of 9.3 days by 2008. For sarcoidosis, length of stay 
declined progressively from 7.5 days in 1993 to 6.2 days by 2008. As shown in Figure 
6B-D, length of stay for the three diagnoses did not appear to differ significantly based on 
region except for IF A for which the length of stay increased dramatically in 2007 with a 
return to baseline a year later in the Northwest region. 
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Table 7 
Primary diagnoses for patients hospitalized with secondary diagnoses of IF A * , PPF*, or 
sarcoidosis (2009)** 
CCS Primary Diagnosis Secondary Diagnosis: % of Total Discharges (%Mortality) 
Code IF A PPF Sarcoidosis 
122 Pneumonia 14.6 (10.4) 12.8 (7.1) 6.5 (1.9) 
131 Respiratory Failure, 10.5 (31.7) 6.2 (21.7) 2.6 (11.2) 
Insufficiency, Arrest (adult) 
127 Chronic Obstructive Pulmonary 8.1 9.8 (2.2) 3.7 
Disease and Bronchiectasis 
108 Congestive Heart Failure, 7.0 8.2 (5.4) 4.4 (3.2) 
Non-hypertensive 
2 Septicemia (except in labor) 5.0 (25.2) 4.2 (22.7) 3.1 (10.3) 
106 Cardiac Dysrhythmias 2.9 3.1 (3.3) 2.8 
100 Acute Myocardial Infarction 2.2 2.2 (9.3) 
128 Asthma l.5 2.0 3.7 
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Figure 6 I A. Length of stay during hospitalization for all conditions decreased steadily in the mid-1990s and stabilized at 4.6 days by 
2009. PPF and sarcoidosis had similar average lengths of stay, whereas IFA patients had the longest (-9 days). B-C. Length of stay for 
the three diagnoses did not appear to differ significantly based on region except for IF A for which the length of stay increased 
dramatically in 2007 with a return to baseline a year later in the Northwest region. 
IF A, idiopathic fibrosing alveolitis; PPF, postintlammatory pulmonary fibrosis; Region is defined by the U.S. Census regions 
The length of stay was also analyzed based on the payer (Figure 7 A-C). For the duration 
of the time studied, patients paying with private insurance had the shortest length of stay 
for patients with PPF and sarcoidosis (~5 days for each condition). The length of stay 
varied for IF A, although Medicaid patients generally stayed the longest time in the 
hospital (~1 0 days). Medicaid patients with PPF also had the longest length of stay as 
compared to other payer types (~7 days). Length of stay did not appear to differ 
significantly when the data were analyzed for gender (Figure SA-C). However gender 
did play a role on percent hospital discharges. We saw more female discharges from 
1997 -2002 for IF A, but these values switched in recent years with males comprising the 
majority of hospital discharges (Figure 9A). For PPF and sarcoidosis, there was a ~ 10 to 
35%, respectively, greater percent of female discharges compared to males (Figure 9B-
C). IF A discharges by gender were not as distinct. 
We then determined where the patients were sent after their hospitalization. As 
depicted in Figure 10, most patients with PPF (~65%), IFA (50%), and sarcoidosis 
(~SO%) demonstrated a 'routine discharge' indicating that they returned home with 
routine care. However, this number decreased with time, and by 2009, over 15% of 
patients hospitalized for PPF and IF A were discharged to home health care (Figure lOB). 
A smaller percentage was discharged to another short-term hospital (Figure 10C). For 
PPF and IF A, between 10% and 15% of patients were discharged to another institution, 
such as a nursing home or rehabilitation center; this category has increased I.S% for both 
conditions over the time period examined (Figure 10D). 
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Figure 7 
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Figure 7 I A. LOS varied for IF A, although Medicaid patients generally stayed the longest 
time in hospital (~1 Odays). B. Medicaid patients with PPF also had the longest LOS on 
average (~7 days). B-C. Private insurance had the shortest length of stay on average for 
PPF and sarcoidosis patients (~5 days for each condition). 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis; LOS, 
length of stay 
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Figure 8 
Length of Stay by Gender 
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Figure 8 I A-C. Length of stay did not vary greatly when analyzed by gender for each 
disease. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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Figure 9 
Discharges by Gender 
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Figure 9 I A. There were more female discharges from 1997-2002 for IFA, but these 
values switched in recent years with males comprising the majority of hospital 
discharges. B-C. For PPF and sarcoidosis, there was a ~ 10 to 35%, respectively, greater 
percent of female discharges compared to males. Comparatively, IF A discharges by 
gender were not as distinct. 
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Figure 10 I A. Most patients with PPF (~65%), IFA (50%), and sarcoidosis (~80%) 
demonstrated a 'routine discharge' indicating that they returned home with routine care. 
However, this number decreased with time. B. Over 15% of patients hospitalized for 
PPF and IF A were discharged to home health care. C. The smallest percentage of 
discharges were sent to another short-term hospital. D. For PPF and IF A, between 10% 
and 15% of patients were discharged to another institution, such as a nursing home or 
rehabilitation center; this category has increased 1.8% for both conditions over the time 
period examined. 
IF A, idiopathic fibrosing alveolitis; PPF, postinfiammatory pulmonary fibrosis 
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As expected, a higher percentage of patients with a diagnosis of sarcoidosis were given a 
'routine' discharge with fewer sarcoidosis patients discharged from the hospital to home 
health care or another facility. In terms of patients admitted to the hospital, a small 
percentage (less than ~5%) were admitted from another hospital, while an increasing 
number (reaching ~50%) were admitted from the emergency department (not shown). 
This suggests that there are an increasing number of patients being hospitalized due to 
acute complications. 
IN-HOSPITAL MORTALITY 
As presented in Figure l1A, IF A had the highest in-hospital mortality through the 
time period examined with 14.92%, followed by PPF (6.95%), and sarcoidosis showed 
the lowest mortality (1.2%). There has been a small decline in in-hospital mortality for 
PPF from 9% in 6.95% within the timeframe studied. In-hospital mortality also 
decreased slightly for IFA from 16.89% to 14.92% during the same time interval. In-
hospital mortality for sarcoidosis has dropped from 2.3% to 1.2%. In general, in-hospital 
mortality is higher for men when compared to women for all three diagnoses (Figures 
lIB-D). In terms of in-hospital mortality by age group there did not appear to be a clear 
distinction for IF A (Figure 12A). For PPF the 45-64 age group had the lowest mortality 
apart from 18-44; however since most patients diagnosed with PPF are older, it is 
possible that these were misdiagnoses. The 85+ and 65-84 age groups had similar overall 
in-hospital mortalities for PPF except for a two year time span from 2003-2004 in which 
the percent mortality was greater for the older age group (Figure 12B). These data 
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Figure 11 
In-Hospital Mortality by Disease and Gender 
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Figure 11 I A. IF A had the highest in-hospital mortality through the time period 
examined with 14.92%, followed by PPF (6.95%), and sarcoidosis showed the lowest 
mortality (1.2%). B-D. In general, in-hospital mortality is higher for men when compared 
to women for all three diagnoses. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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Figure 12 
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Figure 12 I A. In tenns of in-hospital mortality by age group there did not appear 
to be a clear distinction for IF A. B._For PPF the 45-64 age group had the lowest 
mortality apart from 18-44; however since most patients diagnosed with PPF are 
older, it is possible that these were misdiagnoses_ The 85+ and 65-84 age groups 
had similar overall in-hospital mortalities for PPF except for a two year time span 
from 2003-2004 in which the percent mortality was greater for the older age 
group. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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suggest that after a certain age (~65 and older) the age of the patient does not playas 
important a role in affecting survival. 
HOSPIT ALIZA nON CHARGES 
Hospitalization charges have increased for all conditions since 1993 reaching 
~$30,000 on average (Figure 13A). Similarly, hospitalization charges also increased for 
IF A, PPF and sarcoidosis. However, while hospitalization charges for PPF ($15,000 to 
over $40,000, 298% increase) and sarcoidosis ($12,563 to over $37,000, 349% increase) 
have increased at a similar rate, hospitalization charges for IF A have increased 
dramatically in recent years. IF A patients are consistently most costly, especially in the 
last two years of the analysis when the in-hospital charges for IF A experienced a sharp 
increase reaching $81,000. Differences in hospitalization charges were noted when data 
were analyzed by region. For sarcoidosis and PPF, hospitalization charges were highest 
in the West and similar trends were noted for IF A although data for the latter diagnosis 
are limited (Figures 13B-D). We also analyzed mean charges by payer (Figure 14A-C). 
For IF A, private insurance charges were consistently one of the highest reaching over 
$100,000 in the past two years. For PPF, Medicaid patients were charged the most on 
average from 1997-2009 and these charges were paralleled and surpassed, in the past 
year, by private insurance charges (which reached almost $60,000 in 2009). Charges for 
uninsured patients on average were the least during the twelve year timespan. 
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Figure 13 
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Figure 13 I A. Hospitalization charges for all conditions, as well as IF A, PPF, and 
sarcoidosis have increased. Hospitalization charges for IF A have increased dramatically 
in the past two years. B-D. For sarcoidosis and PPF, hospitalization charges were highest 
in the West and similar trends were noted for IF A although data for the latter diagnosis 
are limited. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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Figure 14 
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Figure 14 I A. For IF A, private insurance charges were consistently one of the highest 
reaching over $100,000 in the past two years. B. For PPF, Medicaid patients were 
charged the most on average from 1997-2009 and these charges were paralleled and 
surpassed, in the past year, by private insurance charges (which reached almost $60,000 
in 2009). Charges for uninsured patients on average were the least during the twelve year 
timespan. C. For sarcoidosis there is no clear separation of charges by payer, except for 
uninsured patients for the past several years were approximately $10,000 cheaper than 
other payers. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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For sarcoidosis there is no clear separation of charges by payer, except for uninsured 
patients for the past several years were approximately $10,000 cheaper than other payers. 
For IFA (Figure 15A) charges for males have been ~$4,000 higher every year and the gap 
has increased further in the past few years (~$90,000 for males vs. ~$60,000 for females 
in 2009). Mean charges by gender were very similar for males and females for PPF and 
sarcoidosis (Figure 15B-C) and it is not until the past few years that a difference was seen 
(with males having more mean charges for both conditions). The effect of income on 
in-hospital mortality was analyzed (Figure 16A-B) for IF A and PPF. No distinct 
difference was seen for IF A and PPF suggesting that the mortality rate is not affected by 
the patient's income level. 
Considering that there are significant differences in age of diagnosis for IF AlPPF 
(more common in elderly subjects) and sarcoidosis (more common in younger subjects) 
(Figure 17B-D), we analyzed the data for each condition based on the percent discharges 
based on age group and compared this to discharges for all conditions (Figure 17 A). IF A 
and PPF had similar age distribution with the greatest percent of patients being part of the 
65-84 age range (Figure 17B-C). For sarcoidosis, there was a steady increase in the 
percent of 45-64 year old patients, with a corresponding decrease seen in the percent of 
18-44 year old patients (Figure 17D). The decrease in percent discharges of 18-44 year 
old patients might imply that these patients are living longer and, as such, more are 
surviving into older age. The decreasing mortality rate for patients with sarcoidosis also 
supports this idea. However the increasing average age of the American population may 
also be affecting these data. 
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Figure 15 I A. Charges for males have been ~$4,000 higher every year and the gap has 
increased further in the past few years (~$90,000 for males vs. ~$60,000 for females in 
2009). B-C. Mean charges by gender were very similar for males and females for PPF 
and sarcoidosis and it is not until the past few years that a difference was seen (with 
males having more mean charges for both conditions). 
IF A, idiopathic fibrosing alveolitis; PPF, postinfiammatory pulmonary fibrosis 
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Figure 16 I A-B. The effect of income on in-hospital mortality was analyzed for IF A and 
PPF. No distinct difference was seen for IFA and PPF suggesting that the mortality rate 
is not affected by the patient's income level. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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Figure 17 
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Figure 17 I A. Discharges for all conditions saw ~5% increase in discharges for patients 
in the 45-64 age range. B-C. IF A and PPF had similar age distribution with the greatest 
percent of patients being part of the 65-84 age range. D. For sarcoidosis, there was a 
steady increase in the percent of 45-64 year old patients, with a corresponding decrease 
seen in the percent of 18-44 year old patients. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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We further analyzed these trends by detennining the number of discharges, based on 
condition, per million people by state for 2000 and 2010. We arranged the states in order 
of youngest to oldest states (states with a smaller % of the population older than 45 years 
of age were considered younger). It was hypothesized that as the average state age 
increased, that the number of discharges/million people would increase for IF A and PPF 
since these diseases are predominantly seen in elderly. However, for each entity, there 
was no distinct correlation between 'older' states and more discharges/million people 
(Figure 18A-C). 
DISCUSSION 
IPF is a progressive fibrotic lung disorder that affects close to 200,000 Americans 
and many more worldwide. Its high mortality rate, the lack of effective therapies, and 
recent studies showing that IPF incidence is increasing, have prompted much attention. 
However, little is known about IPF hospitalization rates and in-hospital mortality. It was 
our intention to evaluate trends for hospitalization, length of stay, in-hospital mortality, 
and charges for subjects carrying a diagnosis of IPF over the last two decades. However, 
analyzing these parameters remains a difficult task considering the limitations of the 
databases available and the changes that have occurred regarding the diagnosis of IPF 
which limit the accuracy of the classification of this disease in hospital documents for this 
time period. Considering the above, we opted for evaluating hospitalizations related to 
the diagnosis of IF A, which is most compatible with the diagnosis of IPF, and PPF, 
which is likely to include all fonns of pulmonary fibrosis independent of the cause. 
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Figure 18 
Discharges/Million People by Increasing Average State Age 
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Note: States are arranged from left to right by increasing percent state population 65 
years of age and older. 
Figure 18 I A-C. No distinct correlation was seen between states with older populations 
and the number of discharges/million people. 
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis 
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Although it is likely that not all diagnoses of IF A were accurate, the database provides a 
window into the burden of pulmonary fibrosis in this country as it relates to 
hospitalization. 
Analysis of these data revealed that, during the 15 year period considered by the 
HCUPnet Database (1993-2008), there was an increase in hospitalizations related to PPF 
when compared to IF A and sarcoidosis; the latter remaining relatively stable in 
comparison. Most patients in our cohort were hospitalized with other primary diagnoses 
(with PPF, IF A and sarcoidosis listed as secondary diagnoses) suggesting that subjects 
with these conditions are frequently hospitalized due to co-morbidities or the need for 
procedures. It is likely that some patients with IPF hospitalized with a diagnosis of 
pneumonia and congestive heart failure suffered instead from an acute exacerbation of 
IPF [20], but this could not be ascertained. Other co-morbidities included essential 
hypertension, hyperlipidemia, and diabetes; conditions typically seen in the elderly. The 
presence of these conditions is not surprising considering that IPF is more common with 
aging [3]. Secondary diagnoses related to drug toxicity were also relatively common in 
the IF A group, but no data were available for the other two groups. Until recently, 
patients with pulmonary fibrosis were frequently treated with immunosuppressive agents. 
The use of immunosuppressants may explain why in our cohort, up to 16% of patients 
hospitalized for IF A in 2008 suffered from adverse effects of medical drugs, which was 
associated with 18.63% in-hospital mortality. 
Regarding length of stay, we found a 1-3 day higher length of stay for PPF, IFA 
and sarcoidosis when compared to all conditions, with IF A having the highest length of 
stay (7.2 days in 2008). However, over the period of the analysis, length of stay 
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decreased for all three conditions. This is likely due to pressures imposed on physicians 
for decreasing length of stay and to the increasing recognition that many of the co-
morbidities related to these disorders can be treated in the ambulatory setting. No major 
differences were noted when gender was analyzed and when U.S. regions were 
compared. 
We then determined where the patients were sent after their hospitalization. We 
noted that by 2008, over 15% of patients hospitalized for PPF and IF A were discharged 
to home health care, which has been increasing steadily over the years, and a smaller 
percentage was discharged to another short-term hospital. For PPF and IF A, between 
10% and 15% of patients were discharged to another institution, such as a nursing home 
or rehabilitation center. This percentage has not changed much since 1993, but certainly 
adds to the financial burden of families caring for loved ones with these disorders. 
In-hospital mortality was highest in the IFA group (14.92%), while PPF had 
6.95% in-hospital mortality. As expected, a much lower mortality rate was noted for 
sarcoidosis (1.2%). The in-hospital mortality for all groups has declined in the past 
years. Of note, in-hospital mortality for men was much higher than for women. This 
gender-based difference is quite intriguing, and some studies have reported female sex as 
having a protective effect and worse survival in males, but the factors responsible for it 
remain unclear [64, 65]. 
Finally, we examined hospitalization charges which, as expected, have increased 
for all conditions since 1993. Hospitalization charges have also increased for IF A, PPF 
and sarcoidosis. However, while hospitalization charges for PPF and sarcoidosis have 
increased steadily, hospitalization charges for IF A increased dramatically in recent years. 
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IF A patients are consistently most costly, especially in the last two years analyzed when 
the in-hospital charges for IF A experienced a sharp increase reaching $81,000. The 
highest charges were noted for the West region of the U.S. It is unclear how these 
findings are influenced by hospitalizations related to lung transplantation. 
This study has a number of limitations, the most important of which relates to the 
accuracy of diagnosis. Considering the difficulties inherent in the diagnosis of IPF and 
related disorders, and the changes made in the diagnosis and classification of idiopathic 
interstitial pneumonias over the past two decades [3, 60], it is likely that there were 
misdiagnoses present in the database. Also, some patients may have been counted more 
than once since there were no unique patient identifiers [66]. However, many of the 
findings presented were consistent with expectations considering what we know about 
these disorders. For example, mortality was higher in patients with IF A and PPF when 
compared to sarcoidosis, while the sarcoidosis affected more females and younger 
individuals. The data suggest that hospitalization rates for pulmonary fibrotic disorders 
have increased in this country and that these disorders are associated with significant 
mortality and charges. When evaluating hospitalizations where the primary diagnosis 
was IFA or PPF, we estimate that these conditions accounted for 33,513 hospitalizations 
and 205,293.6 hospitalizations days in 2008. About 2,609 of these patients died while in 
the hospital for 7.8% in-hospital mortality. Importantly, the charges of these 




Hospitalization charges, LOS*, and mortality for patients hospitalized for IF A *, PPF*, 
and sarcoidosis (2008)** 
Parameter IFA PPF Sarcoidosis 
Hospitalizations 3,513 28,732 7,588 
LOS (days) 9.3 6 6.2 
Mortality (%) 14.92 6.95 1.2 
Charges ($) 81,000 40,000 37,000 
Overall charges 285 1,149 281 
(Millions of $) 
*** Avg. Charges/ 56,797 229,397 56,039 
Hospital ($) 
*IFA, idiopathic fibrosing alveolitis; PPF, postinfiammatory pulmonary fibrosis; LOS, length of stay 
**[11], ***[67] 
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In conclusion, despite limitations in diagnosis accuracy, our data suggest that 
hospitalization rates for pulmonary fibrosis increased in the past two decades. Despite 
decreases in length of stay and in-hospital mortality, charges have continued to increase 
reaching close to 1.5 billion dollars in 2008. The majority of these patients were 
admitted because of co-morbidities. Considering that we have limited options when 
treating fibrosis, the early identification and efficient treatment of co-morbidities might 
decrease hospitalizations, in-hospital mortality, and overall hospitalization charges for 
patients with pulmonary fibrosis. 
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IDENTIFYING TARGETS FOR INTERVENTION 
Understanding the impact of IPF to the healthcare system and patients is an 
integral step in taking measures to address the burden of this disease. However, any 
potential cure or drug therapy for IPF is likely to stem directly from laboratory research. 
In order to address the need for further understanding of disease pathogenesis, efforts 
were placed to understand the role of the extracellular cysteine/cystine redox potential 
(Eh Cys/CySS). 
Oxidant stress has been implicated in the pathogenesis of IPF. In fact, a clinical 
trial is being conducted by the NIH-sponsored Idiopathic Pulmonary Fibrosis Clinical 
Research Network to test the potential role of an anti-oxidant (N-acetylcysteine) in the 
treatment of this condition; the results of this trial will not be available until late 2013 
[29]. One form of oxidant stress is through oxidation of the Eh Cys/CySS, which reflects 
the predominant low-molecular-weight thiolldisulfide pool in the plasma [68]. Eh 
Cys/CySS has been found to be approximately -80 mV in normal individuals. However, 
the Eh Cys/CySS becomes more oxidized during aging and disease (e.g., cardiovascular 
and pulmonary diseases) as well as the exposure to chemotherapy and agents like tobacco 
smoke and alcohol [69]. 
Roman and colleagues have reported that lung fibroblasts exposed to oxidized Eh 
Cys/CySS increase their proliferation as well as their expression of markers for 
myofibroblast transdifferentiation (i.e., a-smooth muscle actin, fibronectin) [70]. 
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Furthermore, it appears that these changes are mediated by their expression of 
the pro-fibrotic growth factor Transforming Growth Factor~. More recently, the Roman 
group has obtained plasma samples from IPF patients recruited to the IPF trial described 
above and found that most subjects with IPF show oxidation of their Eh Cys/CySS 
(unpublished results). It is for this reason that the Roman laboratory is exploring how 
this form of oxidant stress can affect fibroblast functions. 
Considering the connection between an oxidized Eh Cys/CySS and lung 
fibroblasts, we turned our attention to oxidant stress and its relationship to lung fibrosis 
and lung cancer. Others have reported that IPF subjects have a higher incidence of lung 
cancer compared to controls. Based on the information presented before, we 
hypothesized that oxidation of the Eh Cys/CySS in IPF subjects may stimulate lung 
fibroblasts to secrete agents that could influence the proliferation of cancer cells. This 
hypothesis was tested in vitro as described below. 
METHODS 
CELL CDL TDRE 
We used primary lung fibroblasts (PLF) harvested from mouse lungs as described 
previously [71]. Primary murine fibroblasts were obtained from C57BLl6 mice. Lung 
tissue sections were isolated, washed twice with sterile PBS, resuspended in DMEM 
supplemented with 10% FBS and 1 % antibiotic-antimycotic solution (100 D/ml penicillin 
G sodium, 100 D/ml streptomycin, and 0.25 ~g/ml amphotericin B), and then transferred 
to a tissue culture dish and incubated in a humidified 5% CO2 incubator at 37°C for 1-3 
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weeks to allow for the fibroblasts to migrate out of the tissue sections. Cells used for 
experiments were between passage 3 and 8. 
CREATION OF CONDITIONED MEDIA 
To create the media used to treat the cancer cell lines tested (Lewis Lung 
Carcinoma, H1792 and H460), PLFs were plated (lxl06 cells/well in a 6 well plate) and 
then grown in serum free media for 24 hours. This media was aspirated and the wells 
were gently washed with PBS. Redox media (of varying m V potentials) was then added 
to each of the wells of the plate (described below). Values of -46m V and -80m V were 
chosen for comparison between an oxidized and healthy state, respectively. After 
incubating for 24 or 72 hours in either -46 or -80m V redox media, the supernatant was 
removed and saved. At this point, the supernatant is referred to as 'conditioned media.' 
The conditioned media from the PLFs was then used for experiments with Lewis 
Lung Carcinoma (LLC) cells, which are lung cancer cells harvested from mice, and later, 
with two different human lung cancer cell lines (H460 and H1792). The respective 
cancer cell lines were plated in 96 well plates, grown in complete serum-free/low-protein 
media, and then treated with conditioned media for 24, 48, and 72 hours. After each of 
these time points the cells were tested for differences in proliferation using an A TP 
proliferation assay and apoptosis using a caspase 3/7 assay. 
ATP PROLIFERATION AND CASPASE APOPTOSIS ASSAYS 
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The A TP assay was performed using the protocol defined by Promega for their 
CellTiter-Glo® Luminescent Cell Viability Assay product. Briefly, the assay reagent and 
cell culture plate were allowed to equilibrate to room temperature. One hundred 
microliters of reagent were added per well in the 96-well plate and then the plate was 
mixed gently for 2 minutes to induce lysis. The plate was then allowed to equilibrate to 
room temperature for 10 minutes before luminescence (produced by the luciferase 
reaction) was recorded using a luminometer. The assay reagent generates a signal 
proportional to the amount of A TP present. 
The Caspase-317 assay was performed according to the protocol defined by 
Promega for their Caspase-Glo® 317 Assay as described on their website 
(www.promega.com).Briefly. the caspase reagent and cell culture plate were brought to 
room temperature, 100 microliters of the reagent was added to each well of a 96 well 
plate. The plate was allowed to gently mix for 30 minutes before the luminescence of 
each sample was detected using a luminometer. 
ESTABLISHING EXTRACELLULAR REDOX MEDIA 
The Eh Cys/CySS was manipulated by varying concentrations of cysteine and 
cystine added to cyst(e)ine-free DMEM, which contains 4 mM glutamine, 10 U/ml 
penicillin, and 10 Ilg/ml streptomycin. 
The first step in preparation of Eh Cys/CySS involved creating 10 mM stock 
solutions of cysteine and cystine, respectively. The stock solutions were adjusted to a pH 
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of 7.4 and then sterile filtered. The stock solutions were then added in a precise ratio to 
cystine-free media to create -46 or -80m V redox media. 
CALCULA nON OF EH 
Eh = Eo + RT/2Fln ([cystine]/[cysteine])2 
Eh represents the electromotive force (given in V or m V) relative to a standard 
hydrogen electrode, R is the gas constant, T is the absolute temperature, F is Faraday's 
constant, and Eo is the standard electrode potential (-0.250 V at pH 7.4) for the 
cysteine/cystine redox couple. 
Prior to placing the redox media on the cell line to be tested, the cells were 
starved in complete serum free media for 24 hours. The cells were then washed gently in 
PBS, the PBS was aspirated and then the cells were cultured in the -46 or -80m V redox 
media for 24 hours. 
RESULTS 
First, we tested the effects of normal (-80 mM) and oxidized (-46 mM) Eh 
Cys/CySS media on the proliferation of LLCs. As presented in Figure 19, we found no 
differences in cell proliferation when the cells were treated directly with -46 or -80m V 
redox media at 24, 48 and 72 hours. We, therefore, turned our attention to the effects of 
fibroblast conditioned media on the proliferation of LLCs. We tested the proliferation of 
LLCs cultured with the supernatant derived from lung fibroblasts exposed to normal and 
oxidized Eh Cys/CySS. Specifically, we cultured the fibroblasts in the normal and 
oxidized Eh Cys/CySS media for 24 or 72 hours. The proliferation of LLCs was then 
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Figure 19 
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Figure 19 I A-C. No difference was seen in cell proliferation when LLCs were treated 
directly with -46 or -80m V redox media. LLCs cultured in the presence of conditioned 
media (CM -46 or -80m V) showed a significant decrease in proliferation in the CM 
-46m V compared to the CM -80m V control group. This effect was seen in response to 
conditioned media that was left on primary lung fibroblasts for 72 and 24 hours. 
Note: CM = Conditioned Media (supernatant from -46mV or -80mV treated primary lung 
fibroblast cells). N=5 for each treatment group. Error bars are standard deviations. 
Statistical significance was calculated using a ttest, where p<O.05 was considered 
statistically significant. 
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evaluated for 24, 48, and 72 h. As seen in Figure 19, LLC cells cultured with the 
supernatant of lung fibroblasts exposed to oxidized Eh Cys/CySS (-46m V) showed 
decreased proliferation compared to LLCs cultured in media obtained from fibroblasts 
exposed to a more reduced Eh Cys/CySS (-80m V). This relationship was more 
prominent when the fibroblasts were maintained in culture for 72 hours, rather than only 
24. 
We then tested the effects of these manipulations on human lung cancer cells 
H460 and H1792. Again, we noted that direct exposure of these cells to normal and 
oxidized Eh Cys/CySS had no effect. However, tumor cells exposed to supernatant 
obtained from fibroblasts exposed to oxidized Eh Cys/CySS (indirect exposure) showed 
decreased proliferation when compared to LLC cells exposed to media from fibroblasts 
exposed to normal Eh Cys/CySS (Figures 20-21). 
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Figure 20 
H460 and H1792 (Human Cancer Cell Lines) 
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Figure 20 I A-D. No difference was seen in cell proliferation when H460 or H1792 cells 
were treated directly with -46 or -80m V redox media. Both cell lines cultured in the 
presence of conditioned media (CM -46 or -80m V) showed a significant decrease in 
proliferation in the CM -46m V compared to the CM -80m V control group. However, 
H460 cells only showed a statistically significant decrease in proliferation at 48 hours. 
Note: CM = Conditioned Media (supernatant from -46m V or -80m V treated primary lung 
fibroblast cells). N=5 for each treatment group. Error bars are standard deviations. 
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Figure 21 I A-B. No difference was seen in cell proliferation when H460 or H1792 cells 
were treated directly with -46 or -80m V redox media at 72 hours. Both cell lines cultured 
in the presence of conditioned media (CM -46 or -80m V) showed a significant decrease 
in proliferation in the CM -46m V compared to the CM -80m V control group. 
Note: CM = Conditioned Media (supernatant from -46mV or -80mV treated primary lung 
fibroblast cells). N=5 for each treatment group. Error bars are standard deviations. 




The caspase assay measures the amount of cleaved caspase enzymes, specifically 
caspase-3 and caspase-7, which are the active forms present during programmed cellular 
death. As depicted in Figure 22, we found that apoptosis was not different in tumor cells 
exposed directly to normal versus oxidized Eh Cys/CySS. However, their proliferation 
was decreased when exposed to the conditioned media. Although proliferation was 
decreased, indirect exposure to the redox media (using conditioned media) did not 
differentially affect apoptosis. 
Together, our studies suggest that oxidation of Eh Cys/CySS in subjects with IPF 
may stimulate lung fibroblasts to produce agents that may indirectly influence the 
proliferation of lung cancer cells. Specifically, the secreted agents reduce lung cancer 
cell proliferation. Lung fibroblasts appear to either secrete agents, or metabolize positive 
factors, that affect lung cancer cell proliferation. The difference in proliferation did not 
appear to be affected by oxidation of the Eh Cys/CySS. Thus, we conclude that an 
oxidized Eh Cys/CySS stimulates lung fibroblasts to produce agents, or metabolize 
factors, that decrease tumor cell proliferation through effects on cell cycle rather than by 
inducing apoptosis. Future efforts focusing on the identification of the mechanisms 
responsible for the effects observed could prove beneficial in the field of IPF, since this 
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Figure 22 I Apoptosis was not different in LLCs exposed directly to nonnal versus 
oxidized Eh Cys/CySS. However, their proliferation was decreased when exposed to the 
conditioned media. Although proliferation was decreased, indirect exposure to the redox 
media (using conditioned media) did not differentially affect apoptosis. 
Note: CM = Conditioned Media (supernatant from -46mV or -80mV treated primary lung 
fibroblast cells). LLCs = Lewis Lung Carcinoma Cells. N=4 for each treatment group. 
Error bars are standard deviations. Statistical significance was calculated using a tiest, 
where p<O.05 was considered statistically significant. 
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FUTURE WORK 
As this document suggests, efforts focused on elucidating disease pathogenesis 
and treatment are still greatly needed for tackling IPF as clinical trials have yet to reveal a 
drug to serve as a magic bullet for targeting this condition. There are several clinical 
trials testing new drugs/drug combination therapies, however, these trials are time 
sensitive and often take several years to complete and analyze. The value of these trials 
is great, but efforts should also be focused on determining potential genetic links to IPF. 
Studies of familial IPF have been essential in helping piece together a potential 
mechanism of disease pathogenesis, yet there is still much work that can be done in this 
area. Genetic studies may prove invaluable as a source for identifying genetic links to 
disease. Identifying genes implicated in IPF pathogenesis could provide targets for future 
drug therapies. 
The most common animal model of IPF is the bleomycin model used in rodents. 
However, drug therapies shown to be effective in the bleomycin model have not been 
shown to provide the same clinically meaningful benefits in human studies. Alternative 
animal models, that better recapitulate the pattern of IPF, are needed. It is interesting to 
note that other species develop lung fibrosis. Lung fibrosis has been demonstrated in 
domesticated animals such as cats, dogs, horses and donkey as well as in birds. These 
animals share our environment and may represent models of naturally-occurring disease. 
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If so, evaluating for clues in these models may accelerate discovery in this field, by 
providing a more realistic model of lung fibrosis. 
Considering the ever changing healthcare landscape, it is important that we 
continue to evaluate the impact of IPF on healthcare costs since new information in this 
area may lead to alterations in the way healthcare is delivered in order to provide the best 
care to patients while relieving healthcare organizations and families from unnecessary 
financial burden. Regarding the HCUP database, we propose that further efforts should 
be directed towards determining a connection between states with lower mortality rates 
and differences in treatment/standards of care for IPF patients in that region. It needs to 
be determined if there are specific states with consistently lower percentages of hospital 
mortality. In addition, any association the lowered mortality rates may have with 
lowerlhigher hospital charges, and, most importantly, what is the cause of the lowered 
mortality. Factors such as local lung disease clinics (which may allow for earlier 
detection/treatment of IPF and any comorbidities), different drug combinations, and the 
quality of/access to hospitals are a few of the possibilities that should be considered. 
It is clear that significant advances in the management of IPF will come only 
through rigorous exploration of the basic mechanisms of action responsible for the 
development and progression of IPF. Also, further understanding of the impact this 
disease has on the development of comorbidities such as lung cancer is important. The 
conditioned media model presented here may be used to identify fibroblast-derived 
products that affect lung cancer cell proliferation. 
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CLOSING SUMMARY 
IPF is a chronic progressive fibrotic lung disease. This disease primarily affects 
the elderly and has a median survival of approximately 3 years. There are no drugs that 
have been shown to halt or reverse the progression of this disease and lung 
transplantation is the only approved surgical treatment to extend survival for these 
patients. Patients with IPF are burdened with declining respiratory function, hospital 
charges that far exceed that of most conditions, and are often afflicted with comorbidities 
that further the difficulty of living with the disease. 
Although the current situation for these patients is dire, there is promise in future 
efforts to treat IPF. Emerging clinical trials, increased awareness and research efforts, 
and a greater understanding of disease pathogenesis all point towards improved 
survivability, quality of life, and treatment options for IPF patients in the future. 
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